Remove 2001 Remove Pharmacy Remove Treatment
article thumbnail

Manitoba Judge’s Opinion Reveals Different Side of the CanadaDrugs Case

Policy Prescription

It’s important because this case was wrongly used as a pretext to oppose safe personal drug importation and international online pharmacies, which help Americans afford prescription drugs. Kris Thorkelson never pled guilty to selling counterfeit drugs. clinics in 2011. supply chain.

article thumbnail

Article FDA Thank You The FDA rejected a psychedelic sponsor’s bid for approval. Here are six industry takeaways

Agency IQ

Many commenters took issue with the guidance’s statement that, “The contribution of the psychotherapy component to any efficacy observed with psychedelic treatment has not been characterized. In the clinical studies, this consisted of a four-month course of treatment with three doses of MDMA administered in supervised therapy sessions.

FDA 40
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Article EMA Thank You New EC report dives deep to better understand shortages of critical medicines

Agency IQ

The EC’s assessment of the risk to the supply chain included the number of actual shortages for each medicine, as well as a public health impact assessment conducted by Member States (based on EMA’s guideline using two criteria: the therapeutic indication and availability of alternative treatment options). from a tablet to a capsule).

article thumbnail

Another RICOdiculous Decision

Drug & Device Law

341 (2001). Yet what the plaintiffs were claiming is that, despite Actos’ undisputed effectiveness as a diabetes treatment, no TPP in the country would have purchased it for that purpose because of the 3/10,000 bladder cancer increased risk. the relationship between [plaintiff] and its pharmacy benefit manager. . . 3d at 1251.

article thumbnail

The FDA and Feasible Alternative Designs

Drug & Device Law

151, 163-68 (2001)) (lengthy discussion of FDA regulatory process omitted). In at least the short term, a popular pain reliever would have to be removed from pharmacies. Another recent and thorough treatment of this subject is found in Robinson v. This would run counter to. . . Ethicon, Inc. 2021 WL 5054648 (S.D. Ethicon, Inc.

FDA 59
article thumbnail

A Texas Mess

Drug & Device Law

Alabama State Board of Pharmacy , 61 F.4th by] authoriz[ing] the [HHS] Secretary to limit legal liability for losses relating to the administration of medical countermeasures such as diagnostics, treatments, and vaccines. . . . Okuley’s Pharmacy & Home Medical , N.E.3d 4th 902, 905 (11th Cir.

Vaccine 59